Home | Sitemap | Search | ContactA- A A+
   
 
    Public Member Support us  
 

IBCSG 55-17 TOUCH 

Phase II open-label, multicenter, randomized trial of neoadjuvant palbociclib in combination with hormonal therapy and HER2 blockade versus paclitaxel in combination with HER2 blockade for elderly patients with hormone receptor positive/HER2 positive early breast cancer.

DESIGN

please click on the picture to see a larger version

Lead Trial Coordinator
Holly Shaw

Trial Coordinator
Colleen King

Data Manager
Colleen King


IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email:
ibcsg55_TOUCH@fstrf.org


IBCSG Coordinating Center, Bern, Switzerland
Phone: +41 31 511 94 00
Fax: +41 31 511 94 01
Email:
Touch-monitoring@ibcsg.org

Date of Activation
xx 

Targeted Accrual
xx


News

09.09.2018:
9.9.2018 - RACE FOR LIFE, Bundesplatz Bern

19.06.2018:
PINK GOLFTOUR 2018  

10.06.2018:
32. SCHWEIZER FRAUENLAUF woman 4 woman - walking together, stronger than ever

All News

 
  Print